Meletios A. Dimopoulos, MD, discussed the phase III Boston study presented at the 2020 ASCO Virtual Scientific Program examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.
We have a new triplet—selinexor (Xpovio), bortezomib (Velcade), and dexamethasone—which could be administered for patients who have received 1 to 3 prior lines of therapy. It could be 1 of the treatments that could be used for patients who have been exposed and progress on lenalidomide (Revlimid) maintenance or continuous treatment. I believe it is an additional combination for the treatment of myeloma patients.
It gives another combination. For example, whenever we have patients who progressed on lenalidomide, often times we use a pomalidomide-based regimen. In this case, we could change completely the mode of action, move to a…